IDEXX Laboratories stock price target raised to $830 from $785 at BTIG

Investing.com - BTIG raised its price target on IDEXX Laboratories (NASDAQ:IDXX) to $830.00 from $785.00 on Monday, while maintaining a Buy rating on the veterinary diagnostics company. The new target represents a 15% upside from IDEXX’s current trading price of $722.93, though InvestingPro data suggests the stock is trading above its Fair Value.

IDEXX shares jumped 15% on Monday, adding over $7 billion in market capitalization following the company’s strong third-quarter results. The stock has now gained 75% year-to-date, with InvestingPro data showing a 73.25% return over the past year. The company’s market cap now stands at approximately $57.6 billion.

The company delivered broad-based growth in the third quarter, with recurring consumables increasing 18% year-over-year and reference lab business growing 10% compared to the same period last year.

BTIG noted that the reference lab growth rate was the highest since 2021, when IDEXX benefited from increased pet care demand following the COVID pandemic.

The firm highlighted that IDEXX achieved 13% year-over-year revenue growth despite a 1.2% decline in pet clinical visits during the third quarter of 2025.

In other recent news, IDEXX Laboratories reported strong financial results for the third quarter of 2025, exceeding expectations in both earnings and revenue. The company achieved earnings per share of $3.22, surpassing the anticipated $3.14, resulting in a 2.55% earnings surprise. Revenue reached $1.1 billion, outperforming the forecasted $1.07 billion and marking a 2.8% revenue surprise. Additionally, Stifel raised its price target for IDEXX Laboratories to $775 from $700 while maintaining a Buy rating. This adjustment follows Stifel’s analysis, which anticipates modest improvements in veterinary visits and a favorable pricing environment. These developments reflect IDEXX’s strengthened market positioning. These recent updates have contributed to a positive outlook among investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.